|会社名||Crinetics Pharmaceuticals Inc （クリネティック・ファ―マシュ―ティカルズ）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 クリネティクス・ファーマスーティカル（Crinetics Pharmaceuticals Inc.）は臨床段階の製薬会社である。同社は、特殊内分泌疾患と内分泌関連腫瘍を治療するための薬物の発見及び開発に注力する。同社は、内分泌疾患の治療のためにペプチドGタンパク質共役受容体（GPCR）を標的とする経口非ペプチド化学物質のパイプラインを開発する。同社のリード製品候補は、先端巨大症の治療用に開発されるCRN00808である。また、高インスリン血症のCRN02481と、神経内分泌腫瘍の治療のためのCRN01941の2種類の製品候補を開発する。CRN02481とCRN01941は、発達の前臨床段階にある経口非ペプチド性ソマスタチン受容体である。同社はまた、クッシング病の治療のための非ペプチド製品の開発に関する研究プログラムを実施する。 クリネティック・ファ―マシュ―ティカルズは米国の医薬品企業。臨床段階で、内分泌疾患や内分泌系腫瘍の治療薬の開発・商業化に従事する。同社の候補薬CRN00808は先端巨大症の治療、CRN02481は先天性高インスリン症の治療、またCRN01941は神経内分泌腫瘍の治療に使用される。本社所在地はカリフォルニア州サンディエゴ。 Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company|
|本社所在地||10222 Barnes Canyon Road Bldg. #2 San Diego CA 92121 USA|
|代表者氏名||Wendall Wierenga Wendall Wierenga|
|代表者役職名||Chairman of the Board 取締役会会長|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Crinetics Pharmaceuticals Inc revenues increased 25% to $1.1M. Net loss increased from $4.3M to $11M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase from $4.1M to $9.7M (expense) General and administrative - Balancing v increase from $913K to $2M (expense).|
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel - BioSpace 2021/06/22 10:55:43 BioSpace
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel BioSpace
Crinetics Pharmaceuticals synthesizes new melanocortin MC2 receptor antagonists 2021/06/03 13:58:13 BioWorld
Leerink Partners Maintains Their Buy Rating on Crinetics Pharmaceuticals (CRNX) 2021/05/31 07:58:58 Smarter Analyst
In a report issued on May 27, Joseph Schwartz from Leerink Partners maintained a Buy rating on Crinetics Pharmaceuticals (CRNX), with a price The post Leerink Partners Maintains Their Buy Rating on Crinetics Pharmaceuticals (CRNX) appeared first on Smarter Analyst .
Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from H.C. Wainwright 2021/05/11 10:27:02 Smarter Analyst
H.C. The post Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from H.C. Wainwright appeared first on Smarter Analyst .
Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight 2021/05/27 00:00:00 Benzinga
Los Angeles, USA, May 26, 2021 (GLOBE NEWSWIRE) -- Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight Levoketoconazole is expected to emerge as a potential therapy owing to its novelty and oral RoA, thus expected to gain maximum Cushing's Syndrome patient pool. DelveInsight's ' Cushing's Syndrome Pipeline Insights ' report offers a detailed picture of the emerging therapies expected to enter the Cushing's Syndrome market along with detailed coverage of the pipeline therapies under development in pre-clinical as well as clinical stages of development, partnerships taking place in the domain, recent happenings in space and growth prospects across the Cushing's Syndrome domain. Some of the key highlights of the Cushing's Syndrome Pipeline report: Cushing's Syndrome Pipeline report offers a comprehensive analysis of 10+ key players and 10+ key therapies. Cushing's Syndrome pipeline comprises Relacorilant (Corcept Therapeutics), Levoketoconazole (Strongbridge Biopharma), CRN-04894 (Crinetics Pharmaceuticals), and several others expected to get launched in the next decade.
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update 2020/11/06 13:31:00 GlobeNewswire
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegaly CRN04777 received…
BidaskClub Downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Strong Sell 2020/10/25 06:52:41 Zolmax News
Crinetics Pharmaceuticals (NASDAQ:CRNX) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday, BidAskClub reports. CRNX has been the topic of a number of other reports. Zacks Investment Research cut shares of Crinetics Pharmaceuticals from a “buy” rating to a […]
Crinetics Pharmaceuticals (NASDAQ:CRNX) Downgraded by BidaskClub to Strong Sell 2020/10/24 08:52:44 Stock Observer
BidaskClub cut shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a sell rating to a strong sell rating in a report published on Friday, BidAskClub reports. A number of other research firms have also weighed in on CRNX. Zacks Investment Research lowered shares of Crinetics Pharmaceuticals from a buy rating to a hold rating in a research […]
Is Crinetics Pharmaceuticals (CRNX) Stock a Solid Choice Right Now? 2020/05/14 12:51:00 Zacks Investment Research
Crinetics Pharmaceuticals (CRNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Crinetics Pharmaceuticals, Inc. (CRNX) Upgraded to Buy: Here's What You Should Know 2020/04/17 16:00:07 Zacks Investment Research
Crinetics Pharmaceuticals, Inc. (CRNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 クリネティック・ファ―マシュ―ティカルズ CRNX Crinetics Pharmaceuticals Inc.）